Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.

Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases. Int J Radiat Oncol Biol Phys. 2011 Oct 01; 81(2):506-10.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.